Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle
about
Pathways for aberrant angiogenesis in pancreatic cancerReview article: current treatment and optimal patient management in pancreatic cancer.Autocrine growth factors and solid tumor malignancy.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth.Autocrine ligand binding to cell receptors. Mathematical analysis of competition by solution "decoys".Concepts in Ras-directed therapy.Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer.Biology of pancreatic cancerNovel Ras antagonist blocks human melanoma growth.Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.Self-induction of a/a or alpha/alpha biofilms in Candida albicans is a pheromone-based paracrine system requiring switchingOverexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alphaBlockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomasPrognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study.Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells.Epidermal growth factor receptor expression in pancreatic lesions induced in the rat by azaserineAn evolutionarily conserved enzyme degrades transforming growth factor-alpha as well as insulinProduction of transforming growth factor-alpha in human tumour cell lines.In vivo quantification of tumor receptor binding potential with dual-reporter molecular imagingHigh vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas.Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver.Molecular mechanisms of pancreatic cancer and potential targets of treatment.Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.MGSA/GRO-mediated melanocyte transformation involves induction of Ras expressionEffect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growthGenetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia.Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro.Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.Metabolism addiction in pancreatic cancer.Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors.Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging.Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells.The autocrine loop of epidermal growth factor receptor-epidermal growth factor / transforming growth factor-alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC549.Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo.Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum.Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor alpha.
P2860
Q24800215-0C441841-2CB5-46E6-AD81-9B220C108FC6Q30431857-275B5A0A-B8B7-4341-9761-6D9117C00A5AQ33559452-D79E70D2-ACD0-454C-9521-92562BEA6F29Q33624574-54C5A450-52A5-44E2-8669-86636124842EQ34066456-3883DAF1-7DEC-4B89-84E1-58D114701528Q34088412-967967A1-E7E6-4C59-B2D4-DA638204CC01Q34119565-B56ECE4A-1AC4-45D1-812B-C7938A22D2E2Q34326442-D5C209B4-9168-48F4-A98B-B719B9D34C7CQ34394264-AE66ABDA-644C-4389-9A1D-1C8236247D2FQ34505870-E69AE534-A1C1-491F-8987-ACE632E040E6Q34536583-EA213E6E-E1CA-425E-AFA1-4E3C5DA676B7Q35080875-EC71EA60-92C3-42BC-B751-5BA34E98FC97Q35606708-8C36B58D-30D2-49B9-B522-9EBFCCFEEA91Q35789079-8F1857F2-2877-4C1A-A092-36EBFD1048ECQ35982524-64ADA1A2-ED12-439B-B1D7-C065A8BA7C29Q36078622-0F8CB496-4E5A-41EC-8BE1-41A44E83FE53Q36135637-B3763ECD-6EC7-496F-A572-51D1BFA53533Q36221404-8B32C9AF-D83A-40DD-B254-126764D3EFA6Q36467731-36C0A87B-005F-461A-97BA-4C59B1960CFCQ36479293-104C4156-A2DC-48C1-A544-1B7DEB77FE34Q36485041-8C8392F4-AE56-4182-890F-96BD17EB4E11Q36659097-491C2A40-B482-4FF6-9BDE-864BC0FE41AFQ36758436-F0891271-284F-4BCB-9425-FD403B9666E6Q36765663-29315B69-502E-402E-A8FF-B290BC783176Q37154670-1371A235-FE7B-4F93-B09A-3CFBA6505B24Q37289054-522BFB71-9A6F-43F3-9384-B045098A2F78Q37343012-BE5191E8-DE3D-457F-BFF8-F75C243877A6Q37352738-D7723365-8A8F-4F2E-A6C3-F2822EE2277EQ37377431-5BC9BFBE-264F-4406-92CD-8F4BE5C8460DQ37620679-9BD37B18-5642-4AE6-AB97-4192F74F0D8CQ39269129-4EC2090E-BEEC-435F-9CF0-8B5F4DA4E836Q39324948-30DA3422-5E22-42EC-AC24-C641A171CC4FQ40142332-91C6FACB-7645-4ADF-9826-4EAF1A4ED45DQ40606676-CCCA5EED-7909-4535-BADC-32F430ECD072Q40818487-30A42D35-0117-4393-921C-741A6074AA25Q40871227-C8CA5195-26E9-4E08-B9E0-B3D1C83F0D47Q40893206-C62E01DA-31BB-4C4D-BAAB-8B15C5734F26Q40906936-F5825EF4-BC73-4144-BF56-DD13DFB8D1DEQ41145569-0C7B2238-494E-46EB-8D85-6F294EFABB0DQ41225764-1EA99D59-4E6E-4645-B0CF-4D0CFC1B5907
P2860
Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle
description
1987 nî lūn-bûn
@nan
1987 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Production of transforming gro ...... a superagonist autocrine cycle
@ast
Production of transforming gro ...... a superagonist autocrine cycle
@en
Production of transforming gro ...... a superagonist autocrine cycle
@nl
type
label
Production of transforming gro ...... a superagonist autocrine cycle
@ast
Production of transforming gro ...... a superagonist autocrine cycle
@en
Production of transforming gro ...... a superagonist autocrine cycle
@nl
prefLabel
Production of transforming gro ...... a superagonist autocrine cycle
@ast
Production of transforming gro ...... a superagonist autocrine cycle
@en
Production of transforming gro ...... a superagonist autocrine cycle
@nl
P2093
P2860
P356
P1476
Production of transforming gro ...... a superagonist autocrine cycle
@en
P2093
P2860
P304
P356
10.1073/PNAS.84.21.7567
P407
P577
1987-11-01T00:00:00Z